358 related articles for article (PubMed ID: 29078377)
1. Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure.
Gesmundo I; Miragoli M; Carullo P; Trovato L; Larcher V; Di Pasquale E; Brancaccio M; Mazzola M; Villanova T; Sorge M; Taliano M; Gallo MP; Alloatti G; Penna C; Hare JM; Ghigo E; Schally AV; Condorelli G; Granata R
Proc Natl Acad Sci U S A; 2017 Nov; 114(45):12033-12038. PubMed ID: 29078377
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart.
Granata R; Trovato L; Gallo MP; Destefanis S; Settanni F; Scarlatti F; Brero A; Ramella R; Volante M; Isgaard J; Levi R; Papotti M; Alloatti G; Ghigo E
Cardiovasc Res; 2009 Jul; 83(2):303-12. PubMed ID: 19293247
[TBL] [Abstract][Full Text] [Related]
3. Mixed lineage kinase-3 prevents cardiac dysfunction and structural remodeling with pressure overload.
Calamaras TD; Baumgartner RA; Aronovitz MJ; McLaughlin AL; Tam K; Richards DA; Cooper CW; Li N; Baur WE; Qiao X; Wang GR; Davis RJ; Kapur NK; Karas RH; Blanton RM
Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H145-H159. PubMed ID: 30362822
[TBL] [Abstract][Full Text] [Related]
4. Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca2+ handling and calcineurin-NFAT signaling pathway.
Ding W; Dong M; Deng J; Yan D; Liu Y; Xu T; Liu J
Am J Physiol Heart Circ Physiol; 2014 Sep; 307(5):H792-802. PubMed ID: 25015961
[TBL] [Abstract][Full Text] [Related]
5. Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction.
Dulce RA; Kanashiro-Takeuchi RM; Takeuchi LM; Salerno AG; Wanschel ACBA; Kulandavelu S; Balkan W; Zuttion MSSR; Cai R; Schally AV; Hare JM
Cardiovasc Res; 2023 Feb; 118(18):3586-3601. PubMed ID: 35704032
[TBL] [Abstract][Full Text] [Related]
6. GH-releasing hormone induces cardioprotection in isolated male rat heart via activation of RISK and SAFE pathways.
Penna C; Settanni F; Tullio F; Trovato L; Pagliaro P; Alloatti G; Ghigo E; Granata R
Endocrinology; 2013 Apr; 154(4):1624-35. PubMed ID: 23417421
[TBL] [Abstract][Full Text] [Related]
7. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling.
Bisserier M; Berthouze-Duquesnes M; Breckler M; Tortosa F; Fazal L; de Régibus A; Laurent AC; Varin A; Lucas A; Branchereau M; Marck P; Schickel JN; Deloménie C; Cazorla O; Soulas-Sprauel P; Crozatier B; Morel E; Heymes C; Lezoualc'h F
Circulation; 2015 Jan; 131(4):390-400; discussion 400. PubMed ID: 25369805
[TBL] [Abstract][Full Text] [Related]
8. The C-terminus of the long AKAP13 isoform (AKAP-Lbc) is critical for development of compensatory cardiac hypertrophy.
Taglieri DM; Johnson KR; Burmeister BT; Monasky MM; Spindler MJ; DeSantiago J; Banach K; Conklin BR; Carnegie GK
J Mol Cell Cardiol; 2014 Jan; 66():27-40. PubMed ID: 24161911
[TBL] [Abstract][Full Text] [Related]
9. Improvement of cardiac and systemic function in old mice by agonist of growth hormone-releasing hormone.
Xiang P; Jing W; Lin Y; Liu Q; Shen J; Hu X; Chen J; Cai R; Hare JM; Zhu W; Schally AV; Yu H
J Cell Physiol; 2021 Dec; 236(12):8197-8207. PubMed ID: 34224586
[TBL] [Abstract][Full Text] [Related]
10. Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
Donaldson C; Eder S; Baker C; Aronovitz MJ; Weiss AD; Hall-Porter M; Wang F; Ackerman A; Karas RH; Molkentin JD; Patten RD
Circ Res; 2009 Jan; 104(2):265-75, 11p following 275. PubMed ID: 19074476
[TBL] [Abstract][Full Text] [Related]
11. Cardiac Overexpression of PDE4B Blunts β-Adrenergic Response and Maladaptive Remodeling in Heart Failure.
Karam S; Margaria JP; Bourcier A; Mika D; Varin A; Bedioune I; Lindner M; Bouadjel K; Dessillons M; Gaudin F; Lefebvre F; Mateo P; Lechène P; Gomez S; Domergue V; Robert P; Coquard C; Algalarrondo V; Samuel JL; Michel JB; Charpentier F; Ghigo A; Hirsch E; Fischmeister R; Leroy J; Vandecasteele G
Circulation; 2020 Jul; 142(2):161-174. PubMed ID: 32264695
[TBL] [Abstract][Full Text] [Related]
12. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
[TBL] [Abstract][Full Text] [Related]
13. Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9.
Wei X; Wu B; Zhao J; Zeng Z; Xuan W; Cao S; Huang X; Asakura M; Xu D; Bin J; Kitakaze M; Liao Y
Circulation; 2015 Apr; 131(17):1506-17; discussion 1517. PubMed ID: 25820336
[TBL] [Abstract][Full Text] [Related]
14. Protection of neonatal rat cardiac myocytes against radiation-induced damage with agonists of growth hormone-releasing hormone.
Kiscsatári L; Varga Z; Schally AV; Gáspár R; Nagy CT; Giricz Z; Ferdinandy P; Fábián G; Kahán Z; Görbe A
Pharmacol Res; 2016 Sep; 111():859-866. PubMed ID: 27480202
[TBL] [Abstract][Full Text] [Related]
15. A gene therapeutic approach to inhibit calcium and integrin binding protein 1 ameliorates maladaptive remodelling in pressure overload.
Grund A; Szaroszyk M; Döppner JK; Malek Mohammadi M; Kattih B; Korf-Klingebiel M; Gigina A; Scherr M; Kensah G; Jara-Avaca M; Gruh I; Martin U; Wollert KC; Gohla A; Katus HA; Müller OJ; Bauersachs J; Heineke J
Cardiovasc Res; 2019 Jan; 115(1):71-82. PubMed ID: 29931050
[TBL] [Abstract][Full Text] [Related]
16. SWAP70 Overexpression Protects Against Pathological Cardiac Hypertrophy in a TAK1-Dependent Manner.
Qian Q; Hu F; Yu W; Leng D; Li Y; Shi H; Deng D; Ding K; Liang C; Liu J
J Am Heart Assoc; 2023 Apr; 12(7):e028628. PubMed ID: 36974751
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis.
Aoyama M; Kawase H; Bando YK; Monji A; Murohara T
Circ Heart Fail; 2016 Jan; 9(1):e002081. PubMed ID: 26721911
[TBL] [Abstract][Full Text] [Related]
18. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
19. STEAP3 (Six-Transmembrane Epithelial Antigen of Prostate 3) Inhibits Pathological Cardiac Hypertrophy.
Li PL; Liu H; Chen GP; Li L; Shi HJ; Nie HY; Liu Z; Hu YF; Yang J; Zhang P; Zhang XJ; She ZG; Li H; Huang Z; Zhu L
Hypertension; 2020 Oct; 76(4):1219-1230. PubMed ID: 32862709
[TBL] [Abstract][Full Text] [Related]
20. Accelerated development of pressure overload-induced cardiac hypertrophy and dysfunction in an RyR2-R176Q knockin mouse model.
van Oort RJ; Respress JL; Li N; Reynolds C; De Almeida AC; Skapura DG; De Windt LJ; Wehrens XH
Hypertension; 2010 Apr; 55(4):932-8. PubMed ID: 20157052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
